Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/14/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
64.93(c) 64.89(c) 64.72(c) 64.58(c) 63.54(c) Last
10 302 187 13 301 911 12 569 334 8 523 099 12 058 346 Volume
+0.51% -0.06% -0.26% -0.22% -1.61% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 46 398 M - -
Net income 2021 6 258 M - -
Net Debt 2021 28 505 M - -
P/E ratio 2021 21,8x
Yield 2021 3,10%
Sales 2022 47 435 M - -
Net income 2022 7 704 M - -
Net Debt 2022 18 029 M - -
P/E ratio 2022 15,5x
Yield 2022 3,28%
Capitalization 141 B 141 B -
EV / Sales 2021 3,65x
EV / Sales 2022 3,35x
Nbr of Employees 30 250
Free-Float -
More Financials
Company
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are... 
Sector
Pharmaceuticals
Calendar
02/04Earnings Release
More about the company
Ratings of Bristol-Myers Squibb Company
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about BRISTOL-MYERS SQUIBB COMPANY
01/20BRISTOL MYERS SQUIBB : Receives Approval for Abecma (idecabtagene vicleucel), the First CA..
PU
01/19Ceptur Therapeutics Inc announced that it has received $75 million in funding from a gr..
CI
01/11Evotec, Bristol Myers Expand Neurogenerative Partnership to Include New Targeted Protei..
MT
01/11Biomica Announces Clearance for First-in-Human Phase I Study of BMC-128 in Combination ..
AQ
01/11Evogene's Biomica Gets Israeli Nod To Move Ahead With Cancer Trial
MT
01/10BioAlta, Bristol Myers Squibb Partnering on Potential Cancer Treatments
MT
01/10BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab ..
PR
01/10Bioatla, Inc. Enters into a Clinical Collaboration with Bristol Myers Squibb to Investi..
CI
01/10Century Therapeutics, Bristol Myers Squibb Sign Cancer Research Collaboration Agreement
MT
01/10Century Therapeutics Shares Rise 12% Premarket After Bristol Myers Deal
DJ
01/10BRISTOL MYERS SQUIBB : JP Morgan Presentation
PU
01/10BRISTOL MYERS SQUIBB CO : Regulation FD Disclosure, Financial Statements and Exhibits (for..
AQ
01/10Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to D..
BU
01/10Century Therapeutics and Bristol Myers Squibb Announces Research Collaboration and Lice..
CI
01/10Bristol Myers Squibb to Highlight Long-Term Growth Strategy at J.P. Morgan's 40th Annua..
BU
More news
News in other languages on BRISTOL-MYERS SQUIBB COMPANY
01/11Evotec et Bristol Myers étendent leur partenariat dans le domaine de la neurogénérescen..
01/11Biomica, filiale d'Evogene, reçoit l'autorisation d'Israël d'aller de l'avant avec un e..
01/11Evotec baut Neurologie-Kooperation mit Bristol Myers aus
01/10BioAlta et Bristol Myers Squibb s'associent sur des traitements potentiels du cancer
01/10Bioatla, Inc. entame une collaboration clinique avec Bristol Myers Squibb pour étudier ..
More news
Analyst Recommendations on BRISTOL-MYERS SQUIBB COMPANY
More recommendations
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | BMY | US1101221083 | MarketScreener
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 63,54 $
Average target price 71,88 $
Spread / Average Target 13,1%
EPS Revisions
Managers and Directors
Giovanni Caforio Senior Vice President-US Oncology
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer
Rupert J. Vessey Executive VP-Research & Early Development
Joseph E. Eid Senior VP & Head-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BRISTOL-MYERS SQUIBB COMPANY3.58%141 036
JOHNSON & JOHNSON-3.40%434 036
ROCHE HOLDING AG-4.87%319 830
PFIZER, INC.-10.60%296 303
ABBVIE INC.-2.53%233 325
ELI LILLY AND COMPANY-11.98%220 356